Last updated: September 8, 2026
TVB-2640, now known as denifanstat, is an oral fatty acid synthase inhibitor developed by Sagimet Biosciences for metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH). The drug has generated positive Phase 2b biopsy data but remains investigational, with no FDA approval, commercial sales, Orange Book listing, or established exclusivity period as of June 2024.
Sagimet’s lead development strategy is focused on MASH patients with fibrosis, particularly those with stage F2 or F3 disease. If late-stage trials confirm the Phase 2b findings, denifanstat could compete in a market shaped by resmetirom, GLP-1 therapies, incretin combinations, and emerging anti-fibrotic agents.
What is TVB-2640 and how does denifanstat work?
Denifanstat is a selective inhibitor of fatty acid synthase, or FASN. FASN catalyzes de novo lipogenesis, the process by which cells synthesize fatty acids. In MASH, excessive lipid synthesis contributes to hepatic steatosis, inflammation, hepatocyte injury, and fibrosis.
The development rationale includes several potential effects:
- Reduction of hepatic fat synthesis.
- Lower liver fat content and inflammation.
- Improvement in hepatocyte ballooning and lobular inflammation.
- Potential reduction in fibrotic progression.
- Activity in extrahepatic tissues associated with metabolic disease.
Denifanstat is an oral, once-daily small molecule. Its mechanism differs from resmetirom, which activates thyroid hormone receptor beta, and from GLP-1 receptor agonists, which primarily affect weight, glucose control, and appetite.
Core development profile
| Attribute |
Denifanstat profile |
| Development code |
TVB-2640 |
| International nonproprietary name |
Denifanstat |
| Developer |
Sagimet Biosciences |
| Mechanism |
Selective fatty acid synthase inhibitor |
| Administration |
Oral |
| Lead indication |
MASH with liver fibrosis |
| Regulatory status |
Investigational |
| FDA approval |
None |
| Current commercial status |
Not marketed |
| Primary development stage |
Phase 2b completed; Phase 3 planning required |
| Key trial |
FASCINATE-2 |
| Main safety issue |
Acne and related dermatologic adverse events |
What were the most important denifanstat clinical trial results?
Sagimet reported positive 52-week biopsy results from the Phase 2b FASCINATE-2 trial in 2024. The study evaluated denifanstat in patients with MASH and stage F2 or F3 fibrosis.
The company reported that denifanstat achieved statistically significant improvement in the key histologic measures used in MASH drug development:
- MASH resolution without worsening of fibrosis.
- At least one-stage fibrosis improvement without worsening of MASH.
- A combined response involving both MASH resolution and fibrosis improvement.
The trial also reported reductions in liver fat and improvements in markers of liver injury. These findings supported continued development, but they do not establish approval-level efficacy. FDA approval requires successful late-stage evidence, an acceptable benefit-risk profile, and agreement on the regulatory endpoint package.
FASCINATE-2 development summary
| Parameter |
Publicly reported information |
| Trial phase |
Phase 2b |
| Population |
Patients with MASH and F2-F3 fibrosis |
| Treatment period |
Approximately 52 weeks |
| Primary assessment |
Liver biopsy |
| Histology endpoints |
MASH resolution and fibrosis improvement |
| Reported outcome |
Statistically significant activity on key histologic measures |
| Main tolerability signal |
Acne and dermatologic adverse events |
| Regulatory consequence |
Supports Phase 3 planning, but does not constitute approval |
The clinical profile is commercially relevant because fibrosis improvement remains one of the most valuable endpoints in MASH. Many competing programs reduce liver fat or improve metabolic parameters without demonstrating clear anti-fibrotic activity.
When could denifanstat reach FDA approval?
Denifanstat is not approved and has no publicly established approval date. The likely regulatory sequence is a Phase 3 program followed by a New Drug Application if the confirmatory trials succeed.
A reasonable development timeline is:
| Milestone |
Potential timing |
| Phase 2b data reported |
2024 |
| Phase 3 design and regulatory alignment |
2024-2025 |
| Phase 3 enrollment |
2025-2026 |
| First pivotal readout |
2027-2028 |
| NDA submission |
2028-2029 |
| Potential FDA decision |
2029-2030 |
| Potential U.S. launch |
2029-2030 |
This timeline assumes rapid financing, timely trial recruitment, and no requirement for an additional confirmatory study. MASH trials often face lengthy enrollment because patients must undergo liver biopsy, have defined fibrosis stages, and meet multiple metabolic and hepatic eligibility criteria.
What is the FDA regulatory status of TVB-2640?
Denifanstat has no FDA approval, no approved label, and no commercial indication. Public development materials have emphasized the FDA’s MASH guidance and histologic endpoints used in prior regulatory programs.
Resmetirom, marketed as Rezdiffra by Madrigal Pharmaceuticals, became the first FDA-approved treatment for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis, in combination with diet and exercise, in March 2024.[1] That approval establishes a regulatory precedent but also raises the commercial standard for later entrants.
Denifanstat could seek approval through the traditional NDA pathway. Accelerated approval may be possible if the FDA accepts a surrogate endpoint that is reasonably likely to predict clinical benefit, but the regulatory pathway will depend on the strength and durability of the Phase 3 data.
What patents protect denifanstat?
The public record identifies Sagimet as the principal developer of denifanstat and reflects a broader intellectual-property position covering FASN inhibition, chemical compounds, pharmaceutical compositions, and therapeutic uses. The precise patent estate requires claim-by-claim review across U.S., European, and international prosecution records.
The key patent categories are likely to include:
- Composition-of-matter claims covering denifanstat and related analogues.
- Salt, polymorph, and crystalline-form claims.
- Pharmaceutical composition claims.
- Oral dosing and treatment-method claims.
- MASH, NASH, fibrosis, and oncology indications.
- Manufacturing and synthetic-process claims.
No FDA Orange Book listing exists because denifanstat has not been approved. Consequently, there is no current Orange Book patent certification framework or Paragraph IV litigation directed at an approved denifanstat product.
Patent and exclusivity position
| Issue |
Current status |
| Approved product |
None |
| Orange Book listing |
None |
| FDA regulatory exclusivity |
None currently available |
| Paragraph IV challenges |
None publicly established against an approved product |
| Composition-of-matter protection |
Expected to be central to the estate |
| Method-of-use protection |
Relevant for MASH and fibrosis indications |
| Generic entry |
Not applicable before approval |
| Biosimilar entry |
Not applicable because denifanstat is a small molecule |
The commercial value of the patent estate will depend on the earliest enforceable composition-of-matter expiration, patent-term adjustment, possible patent-term extension, and the breadth of surviving claims after prosecution and litigation.
How strong is the denifanstat patent estate?
The estate has strategic value if the core molecule claims extend materially beyond a potential 2029-2030 launch. Composition-of-matter protection would provide the strongest barrier because generic applicants would need to avoid or invalidate the foundational claims. Method-of-use patents would be weaker if alternative FASN inhibitors or label strategies can reach the same patient population.
The main patent risks are:
- Narrow claim scope after prosecution.
- Prior-art attacks against the FASN inhibitor chemical series.
- Patent expiration before full commercial uptake.
- Generic challenges based on noninfringement or invalidity.
- Limited protection for a broad MASH indication if claims are restricted to particular fibrosis stages.
- Dependence on formulation or dosing patents after core molecule expiry.
Unlike biologic therapies, denifanstat would not receive biosimilar exclusivity or biologic patent protections. Generic competition could be rapid after loss of meaningful small-molecule patent protection.
Which companies are challenging or competing with denifanstat?
Denifanstat is entering a competitive MASH market with different therapeutic mechanisms and development stages.
| Company |
Product |
Mechanism |
Development or commercial position |
| Madrigal Pharmaceuticals |
Resmetirom |
THR-beta agonist |
FDA-approved in 2024 |
| Novo Nordisk |
Semaglutide |
GLP-1 receptor agonist |
MASH development |
| Eli Lilly |
Tirzepatide |
GIP/GLP-1 agonist |
MASH development |
| 89bio |
Pegozafermin |
FGF21 analogue |
Late-stage development |
| Akero Therapeutics |
Efruxifermin |
FGF21 analogue |
Late-stage development |
| Viking Therapeutics |
VK2809 |
THR-beta agonist |
Mid- to late-stage development |
| InventisBio |
Denifanstat-related competitive programs |
Various |
Emerging competition |
| Sagimet Biosciences |
Denifanstat |
FASN inhibitor |
Phase 2b completed |
Resmetirom has the first-mover advantage, but denifanstat could differentiate through its mechanism, oral administration, and possible activity across fibrosis and inflammatory endpoints. Weight loss will also affect prescribing decisions. GLP-1 and incretin therapies may capture patients whose primary treatment objective is obesity or diabetes, while denifanstat could target patients requiring a liver-directed therapy.
What is the market opportunity for denifanstat?
MASH affects a large population, but the near-term treated market will be substantially smaller than total prevalence. Diagnosis, biopsy or noninvasive staging, specialist access, payer restrictions, and competing metabolic therapies will limit initial uptake.
A practical commercial framework is:
| Scenario |
Eligible treated patients by 2035 |
Annual net price |
Peak annual sales |
| Downside |
150,000 |
$15,000 |
$2.3 billion |
| Base case |
400,000 |
$20,000 |
$8.0 billion |
| Upside |
800,000 |
$25,000 |
$20.0 billion |
These figures are scenario estimates, not company guidance. They assume approval for patients with clinically meaningful fibrosis and pricing below or near specialty hepatology levels established by competing products.
Denifanstat’s commercial upside would increase if it demonstrates:
- Histologic fibrosis improvement.
- Benefits in noncirrhotic F2-F3 disease.
- Compatibility with GLP-1 or incretin therapy.
- Limited weight gain and acceptable metabolic effects.
- A clean enough safety profile for chronic use.
- Noninvasive monitoring that reduces the need for repeat biopsy.
Acne could restrict adherence or physician comfort, especially if the adverse event is dose-related or requires dermatologic management. Chronic MASH treatment requires long-term tolerability because the disease progresses over years.
What generic launch risks exist for denifanstat?
Generic launch risk is low before approval and commercial launch because no generic pathway can be practically pursued against an unapproved reference product. After approval, risk will depend on the remaining patent term.
The highest-risk period would begin when the composition-of-matter patent approaches expiry. Generic applicants could file Abbreviated New Drug Applications with Paragraph IV certifications against listed patents. Litigation would likely focus on:
- Validity of the core chemical claims.
- Infringement by generic formulations.
- Scope of fibrosis and MASH method claims.
- Written-description and enablement issues.
- Obviousness based on earlier FASN inhibitor disclosures.
A successful formulation patent could delay entry only if it protects a commercially necessary dosage form. Method-of-use patents may be less effective if generic labels carve out the patented indication.
How does denifanstat compare with resmetirom?
Resmetirom has a major regulatory advantage because it is approved and has established reimbursement pathways. Denifanstat could compete if its fibrosis data are at least comparable and its safety profile is favorable.
| Category |
Denifanstat |
Resmetirom |
| Mechanism |
FASN inhibitor |
THR-beta agonist |
| FDA status |
Investigational |
Approved |
| Administration |
Oral |
Oral |
| Target population |
MASH with fibrosis under development |
Noncirrhotic MASH with F2-F3 fibrosis |
| Key differentiation |
Direct inhibition of fatty-acid synthesis |
Liver-directed thyroid hormone signaling |
| Commercial risk |
Development and safety execution |
Reimbursement, tolerability, and market expansion |
| Generic risk |
No immediate risk before approval |
Longer-term small-molecule risk |
Denifanstat would need to establish either superior efficacy, better tolerability, meaningful combination value, or a lower net price to displace an established resmetirom prescription.
What licensing deals affect TVB-2640?
Denifanstat originated from the 3-V Biosciences research platform and was subsequently advanced by Sagimet Biosciences. Public company materials identify Sagimet as the current developer. The publicly available record does not establish a major late-stage commercialization partnership comparable to a large pharmaceutical co-development agreement.
The absence of a major partner creates both flexibility and financing risk. Sagimet retains strategic control but may need additional capital or a licensing transaction to fund global Phase 3 development and commercialization.
Key Takeaways
- TVB-2640 is denifanstat, an oral FASN inhibitor developed by Sagimet Biosciences.
- The drug produced positive Phase 2b biopsy results in patients with MASH and F2-F3 fibrosis.
- It is not FDA-approved and has no Orange Book listing or current regulatory exclusivity.
- A Phase 3 program is the critical next development step.
- A realistic approval and launch window is 2029-2030 if Phase 3 development begins promptly and succeeds.
- Resmetirom is the principal approved comparator and has a first-mover advantage.
- Commercial peak sales could range from roughly $2 billion to $20 billion depending on efficacy, safety, pricing, reimbursement, and market penetration.
- The patent estate’s value depends primarily on the remaining term and enforceability of composition-of-matter claims.
- Acne and chronic-use tolerability are material commercial risks.
- Biosimilar competition is irrelevant because denifanstat is a small molecule; generic competition would emerge after small-molecule patent expiry.
FAQs About TVB-2640 and Denifanstat
Is TVB-2640 the same drug as denifanstat?
Yes. TVB-2640 is the development code for denifanstat, Sagimet Biosciences’ oral FASN inhibitor.
Has denifanstat been approved for MASH?
No. Denifanstat remains investigational. Resmetirom is the first FDA-approved therapy for adults with noncirrhotic MASH and moderate-to-advanced fibrosis.
What phase is denifanstat in?
Denifanstat completed a positive Phase 2b program, including the FASCINATE-2 biopsy trial. A successful Phase 3 program is required before potential FDA approval.
Could denifanstat be used with GLP-1 drugs?
Combination use is commercially plausible because FASN inhibition and GLP-1 or incretin therapy act through different mechanisms. A combination strategy would require clinical evidence, safety data, and regulatory support.
What is the biggest risk to denifanstat’s value?
The largest risks are failure to reproduce Phase 2b histology results in Phase 3, chronic dermatologic tolerability issues, competition from approved and late-stage therapies, and insufficient patent life at launch.
References
-
U.S. Food and Drug Administration. (2024, March 14). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
-
Sagimet Biosciences Inc. (2024). Sagimet announces positive topline results from the Phase 2b FASCINATE-2 trial of denifanstat in MASH. Company press release.
-
ClinicalTrials.gov. (2024). A study of denifanstat in patients with non-alcoholic steatohepatitis: FASCINATE-2. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., et al. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835.
-
Sagimet Biosciences Inc. (2024). Corporate presentations and investor materials. Company investor-relations materials.